Clinical trial
Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in…
NCT00019968 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00019968 |
|---|---|
| Title | Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg |
| Official title | Phase II Randomized Study of Isolated Limb Perfusion Using Melphalan With or Without Tumor Necrosis Factor in Patients With Unresectable High Grade Soft Tissue Sarcomas of the Extremity |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage IVB Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma, Stage IIC Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage IVA Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma |
| Intervention type | Drug |
| Interventions | melphalan, tumor necrosis factor |
| Start date | Aug 1, 1999 |
| Completion | Mar 1, 2002 |
| First posted | Mar 5, 2007 |
| Last update posted | Oct 31, 2023 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: